Registration Now Open for RECOVER-TLC Kick-off Meeting, September 23-25, 2024
Building on RECOVER’s successes and lessons learned, RECOVER-TLC will test more potential treatments for Long COVID symptoms.
The National Institutes of Health (NIH) is embarking on the next phase of RECOVER. A new program called RECOVER-Treating Long COVID (TLC) will develop and launch additional Long COVID clinical trials.
RECOVER-TLC will be led by The National Institute of Allergy and Infectious Diseases (NIAID), leveraging its expertise in infectious and immunologic diseases and conditions and its experience in conducting COVID-19 clinical trials. Additionally, RECOVER-TLC will adapt the successful processes used in NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program to address newly identified biological mechanisms and unique symptoms associated with Long COVID. While applying innovative approaches and identifying promising drugs and other therapies, RECOVER-TLC will collaborate with existing RECOVER study sites to maintain the involvement of investigators and participants who are deeply invested in Long COVID research and patient care.
The NIH and the Foundation for the National Institutes of Health (FNIH) are inviting Long COVID researchers, healthcare providers, patients, advocacy organizations, industry partners, Federal scientific agencies, and Federal policymakers to help shape RECOVER-TLC. This effort will begin with a RECOVER-TLC kick-off meeting on September 23 through 25, 2024.
This three-day event will take place in person on the NIH campus and virtually. Participants will come together to:
- Make sure RECOVER-TLC applies all the lessons learned over the last three years
- Discuss the structure and governance of RECOVER-TLC
- Survey the current research landscape
- Help plan future NIH Long COVID clinical trials
Registration remains open for virtual only participation.